Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 7, 2014; 20(13): 3516-3524
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3516
Table 1 Virologic and clinical outcomes of hepatitis B virus infection in patients with inflammatory bowel disease undergoing immunosuppressive therapy
Ref.DiseaseAge/sexHBsAg statusHBV-DNA before therapyAnti-TNFαContemporary drugsLAM prophylaxisHBV-DNA reactivationBiochemical reactivation
Esteve et al[66]CD34 M+ ICNAIFXAZTNoYesALT 2089
10.400 pg/mLAST 1561
CD38 M+ ICNAIFXAZTNoYesALT 2225
9000 pg/mLAST 2146
CD26 M+ CHPositiveIFXAZTYesNoNo
del Valle et al[61]CD40 M+ CHPositiveIFXAZTNoNo worseningNo
3.9 × 105 copies/mm3
Ueno et al[64]CD28 F+ ICNAIFXAZTNoYesALT 43
4.5 LEG/mLAST 64
Millonig et al[12]CD50 M+ ICPositiveIFXAZTNoYesALT 983/50
20 IU/mL38000000 UI/mLAST 413/50
Colbert et al[10]CD54 M+ ICNAIFXAZTNoYesALT 124
1.604 pg/mLAST 143
Madonia et al[13]CD41 F- OCNAIFXSteroidsNoYesALT × 10 UNL
AST × 6 UNL
Ojiro et al[63]CD43 F+ ICNAIFXAZTNoYesALT 239
5.4 LGE/mLAST 145
Zeitz et al[11]UC43 MNANASteroids + AZTNoYesALT 3396
110000000 UI/mLAST 2193